Labcorp Holdings (LH) AI Stock Analysis

Labcorp Holdings

(BMV:LH)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Broad-based growth and margin expansionGrowth is broad enough to support durable operating improvement rather than relying on a single product or customer. Revenue expansion combined with higher margins indicates operating leverage and productivity benefits, strengthening the company’s ability to grow earnings and cash flow over the next several quarters.

Negative Factors

PAMA reimbursement pressureThe proposed reimbursement reductions represent a structural pressure on the diagnostics business rather than a temporary fluctuation. Lower Medicare and Medicaid rates could compress revenue and margins across multiple years, requiring productivity savings, growth, and mix improvement to preserve the company’s earnings trajectory.

Labcorp Holdings (LH) vs. SPDR S&P 500 ETF (SPY)

Market Cap: MXN 29.31B
Dividend Yield: 0.66%
Average Volume (3M): 60
Price to Earnings (P/E): 29.5
Beta (1Y): 0.11
Revenue Growth: -4.91%
EPS Growth: 7.33%
Country: Mexico
Employees: 71,000
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Diagnostics & Research

Labcorp Holdings Business Overview & Revenue Model

Company Description

Labcorp Holdings, Inc. offers vital diagnostic laboratory services, enabling medical professionals, healthcare facilities, pharmaceutical firms, scientific investigators, and patients to make well-informed and confident choices. The company commenced...

Labcorp Holdings Earnings Call Summary

Earnings Call Date:Oct 27, 2026(Q3-2026)|% Change Since:0.00%|Next Earnings Date:Feb 10, 2027

Earnings Call SentimentPositive

The call was strongly positive overall. LabCorp reported broad-based revenue growth, margin expansion, 14.5% adjusted EPS growth, higher 2026 guidance, strong diagnostics and biopharma laboratory demand, a robust backlog, and multiple specialty testing and acquisition opportunities. The principal negative issue was the proposed PAMA reimbursement reduction and its estimated $125 million 2027 impact, along with smaller ACA and foreign exchange headwinds. Management emphasized multiple stated offsets, including organic growth, BLS momentum, Launchpad savings, and business development, so the highlights significantly outweighed the lowlights.

Positive Updates

Strong Third-Quarter Financial Performance

Revenue grew 6.9% to approximately $3.8 billion, adjusted operating margin expanded 60 basis points to 15.0%, adjusted EPS increased 14.5% to $4.78, and free cash flow rose to $412 million from $281 million in the prior year.

Negative Updates

Proposed PAMA Reimbursement Cuts

Management expressed disappointment with the proposed PAMA fee schedule changes, which are expected to reduce Medicare reimbursement rates for hundreds of laboratory tests beginning in 2027. The company estimates an approximately $125 million impact in 2027 from traditional Medicare and Medicaid, with incremental but meaningfully smaller impacts in 2028 and 2029.

Company Guidance

For full-year 2026, enterprise revenue is expected to grow 5.9% to 6.7%, including a 30 basis point benefit from foreign currency translation versus a 40 basis point benefit in prior guidance; Diagnostics revenue growth is expected at 5.5% to 6.2%, BLS segment revenue growth at 7.4% to 8.4%, and central lab revenue is expected to grow in the high single digits on an organic constant currency basis while early development is expected to grow in the low single digits. Enterprise margin expansion is expected relative to 2025, Launchpad remains on track for the $125 million full-year savings target, adjusted EPS guidance is $18.30 to $18.70, with an implied growth rate at the midpoint of 12.5%, free cash flow guidance is $1.24 billion to $1.36 billion, capital expenditures are expected to be nearly 4% of revenue, and the full-year adjusted tax rate is expected to be nearly 23%. For 2027, the company estimates the impact of PAMA to be approximately $125 million and expects to offset a portion of that impact.

Labcorp Holdings Risk Analysis

Labcorp Holdings disclosed 45 risk factors in its most recent earnings report. Labcorp Holdings reported the most risks in the "Legal & Regulatory" category.

Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

1 New Risk

1.There have been no material changes in the risk factors that appear in Part I. Item 1A of the Annual Report.Q1, 2026

Labcorp Holdings Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

MX:LH against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DGX	76Outperform	$27.71B	24.74	15.21%	1.34%	9.13%	17.93%
IQV	74Outperform	$44.06B	32.13	21.82%	―	8.88%	13.11%
ICLR	69Neutral	$16.31B	36.13	4.85%	―	0.67%	43.70%
NTRA	67Neutral	$59.72B	-304.63	-11.73%	―	37.82%	28.02%
CRL	58Neutral	$17.16B	-74.26	-7.72%	―	-0.74%	-268.79%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

MX:LH and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
MX:LH	Labcorp Holdings Inc.	6099.00	881.28	16.89%
CRL	Charles River Laboratories Intl	359.41	180.55	100.94%
ICLR	Icon Plc	211.36	42.57	25.22%
DGX	Quest Diagnostics	251.82	75.94	43.18%
IQV	IQVIA Holdings	267.33	53.45	24.99%
NTRA	Natera Inc.	414.30	216.07	109.00%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Labcorp Holdings AI Stock Analysis